Volume Alert - GILD 101.13 Gilead Sciences $GILD Hit a high

New Post Public Reply Private Reply Replies (0) Message Board
leahanne
Volume Alert - GILD 101.13 Gilead Sciences $GILD Hit a high today of 102.16 Closing the day 10:30 at 101.13 -0.93 -0.91% With a day low of 100.31 and a total volume of 4,690,330.

GILD Recent Posts: http://investorshangout.com/Gilead-Sciences-Inc-GILD-54232/

GILD Gilead Sciences Recent Headline News

Early Glance: Biotechnology companies
AP - 47 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 101.03 (-1.03), AMGN: 159.38 (+1.70), CELG: 105.03 (+0.98)

Stock Market News for November 17, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - 1 hr 6 mins ago
Benchmarks finished almost flat on Friday as Eurozone’s soft GDP data offset encouraging economic reports
DHI: 24.39 (+0.01), HAS: 56.37 (+2.35), BIIB: 306.66 (+1.23), VRTX: 112.01 (+0.67), HAL: 50.85 (-4.23), M: 61.75 (-0.30), WMT: 83.27 (+0.31), SLB: 95.97 (+0.65), COG: 33.55 (-0.07), GILD: 101.03 (-1.03), EOG: 96.66 (-1.50), ALXN: 189.14 (+0.38), MRO: 31.81 (-0.55), CSCO: 26.13 (-0.19), BHI: 66.99 (+7.10)

Why Top Dividend Stock Johnson & Johnson Could Plunge in 2015
George Budwell, The Motley Fool - Motley Fool - Mon Nov 17, 7:13AM CST
As the healthcare sector rolls through its third-quarter earnings, a bucolic picture is coming into focus. Earnings across the sector are soaring due to new drug launches, a frenzy of acquisitions, and vast reorganizations that have helped to stem...
JNJ: 108.30 (+0.14), GILD: 101.02 (-1.04), ABBV: 65.21 (+1.21), CELG: 105.03 (+0.98)

3 Stocks the Smartest Investors Are Buying Right Now
Motley Fool Staff - Motley Fool - Mon Nov 17, 6:51AM CST
Stocks have soared to new heights over the last few years. Does this mean there are no longer any good buys out there? According to three of our contributing writers, that's not the case. 1. Broad-market exchange-traded funds ( John Maxfield )...
VOO: 187.26 (-0.07), GILD: 101.02 (-1.04), PFE: 29.96 (-0.38)

Intercept Pharmaceuticals Appoints Lisa Bright as Head of Europe
GlobeNewswire - Mon Nov 17, 5:01AM CST
Intercept Pharmaceuticals (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases, announced today the appointment of Lisa Bright as Senior Vice President and Head of Europe, effective November 17, 2014. Ms. Bright will be a member of the Intercept senior management team and will spearhead Intercept's European operations based in London as the company prepares for the first indication approval and launch of obeticholic acid (OCA).
GILD: 101.02 (-1.04), ICPT: 157.37 (-5.21)

Studies: New Oral HCV Drug is Effective but Expensive; CBCD Reviews a Report
PRWeb - Sun Nov 16, 11:03PM CST
"Infected with the hepatitis C virus (HCV)? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD
GILD: 101.02 (-1.04)

'Fast Money' Recap: Was Friday the Start of a Bull Rally in Gold?
at The Street - Sat Nov 15, 4:00AM CST
The trading panel took a look at gold prices, which climbed 2.3% on Friday, as well as the potential for a pullback in biotech stocks.
AMZN: 320.41 (-7.41), TSRO: 30.43 (+0.81), XBI: 170.32 (+2.40), IBB: 291.50 (+3.33), CELG: 105.03 (+0.98), GILD: 101.02 (-1.04), GLD: 113.81 (-0.66), MCD: 95.82 (-0.39), SLV: 15.41 (-0.22), GDX: 19.02 (unch), TWTR: 40.96 (-0.89), AAPL: 114.28 (+0.10), BABA: 114.63 (-0.47)

Most active Nasdaq-traded stocks
AP - Fri Nov 14, 5:03PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
GILD: 101.02 (-1.04), GERN: 3.04 (+0.28), ARCP: 8.71 (-0.02), MSFT: 49.30 (-0.28), AAPL: 114.28 (+0.10), CSCO: 26.12 (-0.20)

Final Glance: Biotechnology companies
AP - Fri Nov 14, 5:03PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 101.02 (-1.04), AMGN: 159.38 (+1.70), CELG: 105.03 (+0.98)

Midday Glance: Biotechnology companies
AP - Fri Nov 14, 12:17PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
GILD: 101.02 (-1.04), AMGN: 159.38 (+1.70), CELG: 105.03 (+0.98)

Biotech off today led by Biogen
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:00AM CST

BIIB: 306.66 (+1.23), VRTX: 112.01 (+0.67), GILD: 101.02 (-1.04), ALXN: 189.14 (+0.38), AMGN: 159.38 (+1.70), IBB: 291.50 (+3.33), REGN: 407.17 (+11.97), CELG: 105.03 (+0.98)

Gilead Sciences (GILD) Crosses Pivot Point Support at $102.79
Comtex SmarTrend(R) - Fri Nov 14, 8:57AM CST
Shares of Gilead Sciences (NASDAQ:GILD) opened today below their pivot of $104.92 and have already reached the first level of support at $102.79. Investors may be interested in a cross of the next downside pivot targets of $101.38 and $97.84.
GILD: 101.02 (-1.04)

Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences
Alexander J. Poulos - Seeking Alpha - Fri Nov 14, 8:23AM CST
It is not often for one to come across such an explosive growth company such as Gilead Sciences (NASDAQ: GILD ). By virtue of its stronghold on the Hepatitis C market (HCV) combined with its dominant share in the HIV market, GILD has many...
GILD: 101.02 (-1.04), AMGN: 159.38 (+1.70), SNY: 47.32 (+0.64), REGN: 407.17 (+11.97)

Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene
PR Newswire - Fri Nov 14, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), iBio Inc. (NYSE MKT: IBIO), and Celgene Corporation (NASDAQ: CELG). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, November 13, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,652.79, up 0.23% and the NASDAQ Composite closed at 4,680.14, up 0.11%. The S&P 500 finished the session 0.05% higher at 2,039.33. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 783.78, down 0.10%, whereas the index has gained 10.85% in the previous three months. Register for your complimentary reports on these five stocks at:
GILD: 101.02 (-1.04), IBIO: 1.11 (+0.06), ARIA: 6.06 (-0.09), MNKD: 6.16 (unch), CELG: 105.05 (+1.00)

Reveal Earnings Forecast for BlackBerry, Twitter, Alibaba, Sirius XM, Gilead Sciences, and JD.Com
PR Newswire - Fri Nov 14, 7:45AM CST
EarningForecast.com has issued earnings forecast research with special focus on financial performance of the following stocks: BlackBerry (NASDAQ:BBRY), Twitter (NYSE:TWTR), Alibaba (NYSE:BABA), Sirius XM (NASDAQ:SIRI), Gilead Sciences (NASDAQ:GILD), and JD.Com (NASDAQ:JD).
GILD: 101.03 (-1.03), BBRY: 10.96 (-0.24), JD: 25.52 (-1.49), TWTR: 40.96 (-0.89), SIRI: 3.50 (-0.03), BABA: 114.64 (-0.46)

The Post AASLD Annual Meeting Hepatitis C Landscape
Leonard Yaffe - at Seeking Alpha - Fri Nov 14, 5:15AM CST

JNJ: 108.30 (+0.14), GILD: 101.03 (-1.03), MRK: 59.74 (+0.67), ABBV: 65.22 (+1.22)

If Gilead Has The Ace, Is AbbVie Holding The Big Joker?
Shock Exchange - at Seeking Alpha - Fri Nov 14, 1:55AM CST

GILD: 101.03 (-1.03), ABBV: 65.22 (+1.22)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PMET's High-Stakes Call on Shaakichiuwaanaan Update

Updated Category News Views 51

Inside PMET Resources' Critical Investor Briefing Now, this is the kind of investor chatter that cuts to the core of PMET's game plan. We're talking the big guns coming out with PMET Resources (TSX: PMET) as they gear up for what's poised to be a tell-all investor teleconference about their Shaakichiuwaanaan Project. Yep, mark your calendars because on Tuesday, November...

Continue Reading
Elong Kicks Off Central Asia Strategy with Almaty Launch

Updated Category News Views 70

Elong's Strategic Move into Central Asia When a company like Elong Hotel Technology decides to plant its flag in Central Asia, it’s more than just another overseas venture. This brand launch in Almaty is a bold statement—a signal that they're here to shake things up in a region ripe for development but lacking in hotel chains. With only about 20% penetration for local...

Continue Reading
Jubilant Eyes MPN Breakthrough with JBI-802 Data at ASH

Updated Category News Views 68

Presenting the Case for JBI-802 From the bustling circus of drug development, here comes Jubilant Therapeutics, strutting their stuff with JBI-802, a dual inhibitor designed to tackle myeloproliferative neoplasms (MPNs) with a one-two punch. Now, they're set to drop some spicy deets at the 68th ASH Annual Meeting in New Orleans this December. So what's the fuss about?...

Continue Reading
myKaarma's Off-Site Wash: A Game Changer for Dealers

Updated Category News Views 37

myKaarma Offers Time and Convenience Boost with Wash Option When was the last time a car dealership didn't have folks lined up waiting for a wash? Dragging out your car's service longer than a Sunday sermon. But today, myKaarma, the folks behind dealership customer interaction magic, cracked open another bottle of convenience with their latest offering: off-site,...

Continue Reading
Lyons Steers Home Services Brands to New Franchise Heights

Updated Category News Views 87

Big Changes Ahead for Home Franchise Concepts It's a fresh dawn over at Home Franchise Concepts, and Cory Lyons has been tapped to lead four pivotal brands as their new Brand President. Now, if you're looking at this lineup—Kitchen Tune-Up, Bath Tune-Up, The Tailored Closet, and PremierGarage—you know there's more than just nails and hammers involved. Lyons isn't just...

Continue Reading
Dixie Group Gears Up for Q3 Earnings Call Reveal

Updated Category News Views 105

Anticipation Builds for The Dixie Group's Q3 Results Ah, the smell of anticipation in the air—it's earnings season again, folks! For those keeping a keen eye, The Dixie Group, Inc. (OTCQB: DXYN) sets the stage for the big unveil of its 2026 third-quarter results. They're rolling out the red carpet for investors on Thursday, November 12, 2026, at 11:30 a.m. Eastern Time,...

Continue Reading
MoreBetter's Therapy Co-Investment: A Big Bet on Patient Data

Updated Category News Views 23

Diving Into Uncharted Waters with Bold Moves MoreBetter is stepping right into the murky, unpredictable world of longevity, peptide, and psychedelic therapies with a fresh initiative—the RWE Co-Investment Program. This isn't your run-of-the-mill study announcement; it's a gutsy leap into largely unexplored areas of patient-reported outcomes and real-world evidence. A...

Continue Reading
Mass-Vac Unleashes Advanced Vacuum Protection

Updated Category News Views 92

Introducing a Heavy-Duty Defender for Lab Systems When it comes to safeguarding central laboratory vacuum systems, you can bet there’s more at play than meets the eye. Mass-Vac, Inc., steps up and doesn't mess around with their latest innovation—the MV Multi-Trap® Vacuum Inlet Trap. Climbing aboard in November 2026, this stout guardian against contamination is out to...

Continue Reading
Retail's AI Ambitions Clash with In-Store Data Realities

Updated Category News Views 127

AI's Lofty Goals Meet Retail's Messy Reality I swear, all this chatter about AI transforming retail sounds grand until you dig into the messy trenches, right? This latest Scandit survey lays it bare: retailers have got their AI visions sprinting ahead of the stock data realities inside their stores. Seems those shiny new systems rely on stock data that matches what's...

Continue Reading
Gen Z, Millennials Lean on AI Amid Fiscal Crunch

Updated Category News Views 78

AI Meets Gen Z and Millennials: A Financial Lifeline? Here's an angle you might not expect: young folks are all in for AI, particularly when it comes to navigating banking services. Picture it—18 to 34-year-olds embracing AI far more openly than their older counterparts. We're talking 60% of them valuing 24/7 availability in AI services compared to just 47% of those...

Continue Reading
ws Articles" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles